drugset / Trial / NCT01269684

Immediate Conversion From Tacrolimus to Everolimus in Stable Maintenance Renal Transplant Recipients

NCT01269684

Phase 4 Withdrawn Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to investigate safety and tolerability of an immediate conversion from Tacrolimus to everolimus in stable renal allograft recipients. Interest in developing CNI-free regimens using other agents such as the proliferation signal inhibitor everolimus.

Timeline

Start
2008-08
Primary completion
2008-08
Completion
2008-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Everolimus Small molecule 1.5 mg

Indications

No indication recorded.